TB-500 (Thymosin Beta-4) Canada | Research Guide
2 Jul 2026TB-500 (Thymosin Beta-4) Canada | Research Guide
Canada Research Guide Research Use Only Updated September 2026
TB-500 (Thymosin Beta-4) Canada Research Guide
TB-500 is one of the most-studied peptides in tissue-repair and regeneration research, and among the most frequently searched recovery compounds in the Canadian market. This guide covers its relationship to thymosin beta-4, its actin-regulating mechanism, the preclinical evidence base for cell migration and angiogenesis, why it is so often paired with BPC-157 in the so-called Wolverine Blend, and the purity and sourcing standards Canadian researchers should apply.
Direct Answer: TB-500 is a synthetic peptide based on thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-sequestering protein. It is associated with the actin-binding region of Tβ4 that drives much of the protein's activity in cell migration, angiogenesis (new blood vessel formation), and wound repair in preclinical models. In laboratory and animal studies, thymosin beta-4 has been reported to accelerate wound healing, promote endothelial cell migration and blood-vessel sprouting, and reduce inflammatory markers. It is widely co-studied with BPC-157 in tissue-repair research. TB-500 is not stocked here as a single-compound vial — it is supplied inside the Wolverine Blend, lot HEAL-0626-01, which returned 98.64% combined purity by HPLC-UV at 214 nm at Testides (Toronto).
TB-500 is available in our pre-blended recovery formulation
Wolverine Blend (BPC-157 + TB-500) BPC-157 10mg Lab Results / COAsJump to a section
What Is TB-500?
TB-500 is the common research-market name for a synthetic peptide derived from thymosin beta-4 (Tβ4), the most abundant member of the beta-thymosin family and the principal G-actin-sequestering peptide in mammalian cells. Tβ4 is a ubiquitous 43-amino-acid, ~5 kDa polypeptide involved in cell proliferation, migration, and differentiation. Research has localized much of its regenerative activity to a short actin-binding motif within the molecule, and TB-500 is associated with this active region.
Because Tβ4 regulates the actin cytoskeleton — the internal scaffolding cells use to move — it sits upstream of processes central to tissue repair: cell migration into a wound, the formation of new blood vessels, and remodeling of the extracellular matrix. This is why TB-500 is studied across dermal, cardiac, corneal, and musculoskeletal repair models.
| Property | Detail |
|---|---|
| Compound Name | TB-500 (thymosin beta-4 / Tβ4) |
| Molecular Class | Actin-sequestering / actin-binding peptide |
| Parent Protein | Thymosin beta-4 (43 amino acids, ~5 kDa) |
| Primary Research Actions | Cell migration, angiogenesis, wound repair |
| Commonly Paired With | BPC-157 (recovery research pairing) |
| Research Format | Lyophilized powder |
| Use Context | Laboratory and non-clinical research only |
Mechanism of Action: Actin, Migration & Angiogenesis
Thymosin beta-4's defining biochemical role is binding and sequestering monomeric G-actin, buffering the pool of actin available for filament assembly. By regulating actin dynamics, Tβ4 influences how readily cells can reorganize their cytoskeleton to migrate — a rate-limiting step in tissue repair. Research using naturally occurring Tβ4, proteolytic fragments, and synthetic peptides has shown that a seven-amino-acid actin-binding motif is essential for its angiogenic activity, with the isolated motif displaying near-identical activity to the full peptide in endothelial migration and vessel-sprouting assays.
| Research Pathway | Observed Effect (Preclinical) |
|---|---|
| Actin regulation | Sequesters G-actin; enables cytoskeletal remodeling and cell motility |
| Cell migration | Stimulates keratinocyte and endothelial cell migration in chamber assays |
| Angiogenesis | Promotes endothelial migration, tubule formation, and aortic-ring sprouting |
| Wound repair | Accelerates healing in animal wound models |
| Inflammation | Associated with reduced inflammatory markers in dermal repair assays |
All mechanisms described are drawn from in-vitro and animal-model research and are presented for laboratory research context only.
Preclinical Evidence Base
Thymosin beta-4 has a substantial peer-reviewed literature spanning wound healing, angiogenesis mechanisms, and cardiac repair. A 2026 scoping review catalogued 80 thymosin beta-4 / TB-500 studies across tissue healing, regeneration and musculoskeletal repair — and its findings are a useful corrective. The evidence base was weighted toward in-vitro and mixed study designs, concentrated on wound/skin, vascular and ocular tissue, and addressed Tβ4 far more often than TB-500 itself: only one included study examined TB-500 directly, human evidence was largely restricted to eye and wound-healing contexts, and musculoskeletal applications such as tendon and ligament repair received sparse attention.
| Study Focus | Key Finding | Reference |
|---|---|---|
| Wound healing (animal models) | Reported that thymosin beta-4 accelerated wound healing in animal models relative to controls | Malinda et al., J Invest Dermatol 1999 (PMID: 10469335) |
| Angiogenesis (actin-binding motif) | Identified the seven-amino-acid actin-binding motif as essential for Tβ4's angiogenic activity in endothelial migration and vessel-sprouting assays | Philp et al., FASEB J 2003 (PMID: 14500546) |
| Angiogenesis mechanisms review | Reviewed how Tβ4 regulates angiogenesis and its role in wound healing and cardiovascular repair, including ischaemic heart models | Smart et al., Angiogenesis 2007 (PMID: 17632766) |
| Tissue healing and musculoskeletal repair (scoping review) | Included 80 studies; evidence weighted toward in-vitro and mixed designs and toward Tβ4 rather than TB-500, with only one included study addressing TB-500 directly and limited human evidence relevant to musculoskeletal repair | McGuire et al., Applied Sciences 2026 (DOI: 10.3390/app16126202) |
The BPC-157 + TB-500 Recovery Pairing
In recovery-research circles, TB-500 is most often discussed alongside BPC-157 — a pairing informally called the “Wolverine Blend.” The two compounds are studied together because their mechanisms are complementary rather than overlapping:
| Compound | Primary Research Mechanism | Typical Research Focus |
|---|---|---|
| BPC-157 | Cytoprotection and angiomodulation (studied via VEGFR2/nitric-oxide pathways) | Gastrointestinal protection, tendon and ligament models |
| TB-500 (Tβ4) | Actin-regulated cell migration and angiogenesis | Systemic wound healing, cell migration, vascularization |
| Combined interest | Distinct but converging tissue-repair pathways | Broad soft-tissue and recovery research |
This complementary rationale is why many Canadian suppliers stock the two as a pre-blended formulation. Our Wolverine Blend (BPC-157 + TB-500) combines both in a single lyophilized 10mg vial for researchers studying the pairing.
Purity and Documentation for TB-500 Research
| Quality Signal | Why It Matters for TB-500 |
|---|---|
| Measured HPLC purity, reported to the decimal | Confirms correct peptide synthesis and low process-related impurities |
| Mass spectrometry | Verifies molecular identity and expected mass of the peptide |
| Batch-specific COA | Lot traceability for reproducible research results |
| Third-party testing | The Wolverine Blend lot HEAL-0626-01 was tested by Testides (Toronto) at 98.64% combined. Neither Testides nor Janoshik Analytical is accredited to ISO/IEC 17025. |
View current lab results and COA documentation → · BPC-157 vs TB-500 comparison
Storage and Handling
| Condition | Recommendation |
|---|---|
| Lyophilized (unopened) | -20°C long-term; 2-8°C short-term |
| Light & freeze-thaw | Protect from light; minimize freeze-thaw cycles. This guide covers sealed-vial storage only and contains no reconstitution or preparation guidance. |
TB-500 in the Recovery Peptide Spectrum
| Feature | BPC-157 | TB-500 (Tβ4) |
|---|---|---|
| Origin | Gastric peptide fragment | Thymosin beta-4 fragment |
| Core mechanism | Cytoprotection / angiomodulation | Actin regulation / cell migration |
| Most-studied tissues | Gut, tendon, ligament | Skin, cardiac, systemic vasculature |
| Research role in the pairing | Local protection & repair signaling | Migration & new vessel formation |
Frequently Asked Questions
What is TB-500 used for in research?
What is the difference between TB-500 and thymosin beta-4?
Why is TB-500 paired with BPC-157?
Is TB-500 legal to purchase in Canada for research?
What purity should I look for?
How should TB-500 be stored?
How fast does TB-500 ship in Canada?
Related Research Resources
References
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368. PubMed: 10469335
- Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. 2003;17(14):2103-2105. PubMed: 14500546
- Smart N, Rossdeutsch A, Riley PR. Thymosin beta4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis. 2007;10(4):229-241. PubMed: 17632766
- McGuire F, Hughes E, Maak T, Cushman DM. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Applied Sciences. 2026;16(12):6202. DOI: 10.3390/app16126202
For laboratory and research use only. ThePeptide.ca materials are not represented as approved for human use, veterinary use, or therapeutic application. Preclinical and clinical findings are referenced for research context only.
Shop This Compound
Every lot carries a published, batch-specific lab report, dispatched within 48 hours from BC with free tracked shipping Canada-wide and no minimum: Wolverine Blend — BPC-157 + TB-500. Browse the full collection →